Literature DB >> 118929

Alternate complement pathway activation by group A streptococci: role of M-protein.

A L Bisno.   

Abstract

Avirulent strains of group A streptococci readily activate the complement system in normal human serum via the alternate complement pathway (ACP). Virulent M-positive group A streptococci are much less potent as activators of the ACP. The ability of M-positive streptococci to activate the ACP is enhanced by trypsinization or mild peptic digestion. The latter treatment removes the serologically active and antiphagocytic type-specific moieties of M protein, but retains the surface fuzzy layer. The phagocytosis of avirulent streptococci is markedly enhanced by preopsonization in serum chelated with Mg-ethylene glycol tetraacetic acid (classic complement pathway blocked) but not in serum devoid of heat-labile factors. These studies suggest that the function of M protein as a virulence factor may be mediated, at least in part, by its ability to retard interaction of ACP components with structures present on the streptococcal cell surface.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 118929      PMCID: PMC414743          DOI: 10.1128/iai.26.3.1172-1176.1979

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  14 in total

1.  Pneumococcal type-associated variability in alternate complement pathway activation.

Authors:  D P Fine
Journal:  Infect Immun       Date:  1975-10       Impact factor: 3.441

2.  NATURAL RESISTANCE OF GERM-FREE MICE AND COLOSTRUM-DEPRIVED PIGLETS TO GROUP A STREPTOCOCCI.

Authors:  G H STOLLERMAN; R D EKSTEDT; I R COHEN
Journal:  J Immunol       Date:  1965-07       Impact factor: 5.422

3.  Activation of the alternative complement pathway by Haemophilus influenzae type B.

Authors:  P H Quinn; F J Crosson; J A Winkelstein; E R Moxon
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

4.  Evidence for quantitative variability of bacterial opsonic requirements.

Authors:  J C Guckian; W D Christensen; D P Fine
Journal:  Infect Immun       Date:  1978-03       Impact factor: 3.441

5.  Activation of the alternative complement pathway by a streptococcal lipoteichoic acid.

Authors:  B A Fiedel; R W Jackson
Journal:  Infect Immun       Date:  1978-10       Impact factor: 3.441

6.  Opsonic activity in human serum chelated with ethylene glycoltetra-acetic acid.

Authors:  A Forsgren; P G Quie
Journal:  Immunology       Date:  1974-06       Impact factor: 7.397

7.  Activation of the alternate complement pathway by peptidoglycan from streptococcal cell wall.

Authors:  J Greenblatt; R J Boackle; J H Schwab
Journal:  Infect Immun       Date:  1978-01       Impact factor: 3.441

8.  Role of complement in host defense against experimental disseminated candidiasis.

Authors:  J A Gelfand; D L Hurley; A S Fauci; M M Frank
Journal:  J Infect Dis       Date:  1978-07       Impact factor: 5.226

9.  Accessory plasma factors involved in the bactericidal test for type-specific antibody to group A streptococci. I. A typical behavior of some human and rabbit bloods.

Authors:  G H STOLLERMAN; F S KANTOR; B D GORDON
Journal:  J Exp Med       Date:  1958-10-01       Impact factor: 14.307

10.  Studies on the pathogenicity of group A streptococci. II. The antiphagocytic effects of the M protein and the capsular gel.

Authors:  M J FOLEY; W B WOOD
Journal:  J Exp Med       Date:  1959-10-01       Impact factor: 14.307

View more
  42 in total

1.  Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae.

Authors:  A H Tu; R L Fulgham; M A McCrory; D E Briles; A J Szalai
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

Review 2.  The Jeremiah Metzger Lecture. Microbial defenses against killing by phagocytes.

Authors:  G L Mandell; M O Frank
Journal:  Trans Am Clin Climatol Assoc       Date:  1992

3.  Virulent human strains of group G streptococci express a C5a peptidase enzyme similar to that produced by group A streptococci.

Authors:  P P Cleary; J Peterson; C Chen; C Nelson
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

4.  M protein of the group A Streptococcus binds to the seventh short consensus repeat of human complement factor H.

Authors:  T K Blackmore; V A Fischetti; T A Sadlon; H M Ward; D L Gordon
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

Review 5.  Common themes in microbial pathogenicity.

Authors:  B B Finlay; S Falkow
Journal:  Microbiol Rev       Date:  1989-06

Review 6.  Molecular aspects of the phagocytosis resistance of group A streptococci.

Authors:  B N Manjula
Journal:  Eur J Epidemiol       Date:  1988-09       Impact factor: 8.082

7.  Expression of M type 12 protein by a group A streptococcus exhibits phaselike variation: evidence for coregulation of colony opacity determinants and M protein.

Authors:  W J Simpson; P P Cleary
Journal:  Infect Immun       Date:  1987-10       Impact factor: 3.441

8.  Antiopsonic activity of fibrinogen bound to M protein on the surface of group A streptococci.

Authors:  E Whitnack; E H Beachey
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

9.  Expression of the Arp protein, a member of the M protein family, is not sufficient to inhibit phagocytosis of Streptococcus pyogenes.

Authors:  L K Husmann; J R Scott; G Lindahl; L Stenberg
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

10.  Streptococcus uberis resists the bactericidal action of bovine neutrophils despite the presence of bound immunoglobulin.

Authors:  J A Leigh; T R Field
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.